Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
Ji‐Youn Han(National Cancer Centre Japan), Ho‐Young Lee(Cancer Clinic)
Cited by 97
Related Papers
Molecular targeted therapy for anticancer treatment
|Experimental & Molecular Medicine|2022|495
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413
Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
|Cancer Research|2006|336
Effects of Deguelin on the Phosphatidylinositol 3-Kinase/Akt Pathway and Apoptosis in Premalignant Human Bronchial Epithelial Cells
|JNCI Journal of the National Cancer Institute|2003|257